PPA
JBIO

Parametric Portfolio Associates’s Jade Biosciences JBIO Stock Holding History

Parametric Portfolio Associates’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,029
Closed -$424K – 3681
2021
Q4 		$424K Sell
1,029
-3,018
-75% -$1.53M ﹤0.01% 3131
2021
Q3 		$2.97M Buy
+4,047
New +$2.27M ﹤0.01% 2175

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Parametric Portfolio Associates's JBIO Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Jade Biosciences (JBIO) in Q1 2022, closing a stake of 1,029 shares — an estimated $424K sold.

Parametric Portfolio Associates first reported a position in JBIO in Q3 2021 and held it in 2 quarters. The position peaked at $2.97M in Q3 2021. 45 funds tracked by Wall St. Rank hold JBIO as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Jade Biosciences position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 1,029 Jade Biosciences shares in Q1 2022, an estimated $424K.
  • Parametric Portfolio Associates first reported a position in Jade Biosciences in Q3 2021 and held it in 2 quarters.
  • Parametric Portfolio Associates's Jade Biosciences position peaked at $2.97M in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.